Table 1.
Demographics, clinical characteristics, and treatment regimens of patients with GC/GEJC/EAC
| Characteristic | Total | France | Germany | UK | US | Japan | China |
|---|---|---|---|---|---|---|---|
| n = 995 | n = 203 | n = 200 | n = 204 | n = 143 | n = 45 | n = 200 | |
| Age, years | |||||||
| Mean (SD) | 65.0 (10.3) | 65.0 (9.7) | 65.0 (9.5) | 67.7 (9.7) | 67.9 (9.2) | 70.2 (8.6) | 59.0 (10.9) |
| Median (IQR) | 66.0 (59–72) | 67.0 (60–71) | 65.0 (58–71) | 68.5 (64–74) | 68.0 (61–73) | 70.0 (64–78) | 60.0 (51–67) |
| Male, n (%) | 691 (69.5) | 150 (73.9) | 146 (73.0) | 132 (64.7) | 104 (72.7) | 28 (62.2) | 131 (65.5) |
| Female, n (%) | 304 (30.5) | 53 (26.1) | 54 (27.0) | 72 (35.3) | 39 (27.3) | 17 (37.8) | 69 (34.5) |
| Confirmed diagnosis, n (%) | 995 | 203 | 200 | 204 | 143 | 45 | 200 |
| GC | 610 (61.3) | 130 (64.0) | 121 (60.5) | 100 (49.0) | 57 (39.9) | 31 (68.9) | 171 (85.5) |
| GEJC | 268 (26.9) | 54 (26.7) | 59 (29.5) | 64 (31.4) | 56 (39.2) | 8 (17.8) | 27 (13.5) |
| EAC | 117 (11.8) | 19 (9.4) | 20 (10.0) | 40 (19.6) | 30 (21.0) | 6 (13.3) | 2 (1.0) |
| Lauren classification, n (%) | 873 | 181 | 195 | 170 | 100 | 39 | 188 |
| Diffuse | 340 (39.0) | 68 (37.6) | 72 (36.9) | 75 (44.1) | 38 (38.0) | 19 (48.7) | 68 (36.2) |
| Intestinal | 375 (43.0) | 89 (49.2) | 85 (43.6) | 61 (35.9) | 38 (38.0) | 18 (46.3) | 84 (44.7) |
| Mixed | 158 (18.1) | 24 (13.3) | 38 (19.5) | 34 (20.0) | 24 (24.0) | 2 (5.1) | 36 (19.2) |
| HER2 status, n (%) | 995 | 203 | 200 | 204 | 143 | 45 | 200 |
| HER2 positive | 210 (21.1) | 30 (14.8) | 42 (21.0) | 27 (13.2) | 20 (14.0) | 5 (11.1) | 86 (43.0) |
| HER2 status negative or unknown | 785 (78.9) | 173 (85.2) | 158 (79.0) | 177 (86.8) | 123 (86.0) | 40 (88.9) | 114 (57.0) |
| Current therapy, n (%) | 995 | 203 | 200 | 204 | 143 | 45 | 200 |
| Active first-line systemic therapy | 870 (87.4) | 198 (98.0) | 183 (91.5) | 172 (84.3) | 118 (82.5) | 41 (91.1) | 158 (79.0) |
| Best Supportive Care only | 125 (12.6) | 5 (2.5) | 17 (8.5) | 32 (15.7) | 25 (17.5) | 4 (8.9) | 42 (21.0) |
| Current active treatment regimen, n (%) | 870 | 198 | 183 | 172 | 118 | 41 | 158 |
| Anti-angiogenic based | 28 (3.2) | 0 (0.0) | 14 (7.7) | 0 (0.0) | 4 (3.4) | 2 (4.9) | 8 (5.1) |
| Mono chemotherapy | 42 (4.8) | 6 (3.0) | 1 (0.6) | 5 (2.9) | 9 (7.6) | 12 (29.3) | 9 (5.7) |
| Dual chemotherapy | 383 (44.0) | 111 (56.1) | 51 (27.9) | 67 (39.0) | 59 (50.0) | 21 (51.2) | 74 (46.8) |
| Triple chemotherapy | 254 (29.2) | 49 (24.8) | 84 (45.9) | 75 (43.6) | 17 (14.4) | 1 (2.4) | 28 (17.7) |
| Anti-HER2 based | 134 (15.4) | 31 (15.7) | 33 (18.0) | 25 (14.5) | 10 (8.5) | 3 (7.3) | 32 (20.3) |
| Anti-PD1 IO | 29 (3.3) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 19 (16.1) | 2 (4.9) | 7 (4.4) |
EAC Esophageal adenocarcinoma, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, SD Standard deviation, UK United Kingdom, US United States, PD1 IO Programmed cell death protein 1 immuno-oncology